Arrowhead Pharmaceuticals, Inc. Files Definitive Proxy Statement

Ticker: ARWR · Form: DEF 14A · Filed: Jan 26, 2024 · CIK: 879407

Complexity: simple

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Arrowhead Pharmaceuticals, Corporate Governance, Executive Compensation

TL;DR

<b>Arrowhead Pharmaceuticals, Inc. has filed its Definitive Proxy Statement for the period ending January 26, 2024.</b>

AI Summary

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed a Proxy Statement (DEF 14A) with the SEC on January 26, 2024. Arrowhead Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 26, 2024. The filing covers the period ending January 26, 2024. The company's fiscal year ends on September 30. Arrowhead Pharmaceuticals, Inc. was formerly known as Arrowhead Research Corp. The company is incorporated in Delaware.

Why It Matters

For investors and stakeholders tracking ARROWHEAD PHARMACEUTICALS, INC., this filing contains several important signals. This filing is a routine proxy statement, indicating the company is seeking shareholder approval for matters such as director elections and executive compensation. As a DEF 14A filing, it provides detailed information about corporate governance and executive compensation, which is crucial for investors to understand how the company is managed and how executives are incentivized.

Risk Assessment

Risk Level: low — ARROWHEAD PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a routine DEF 14A, which typically contains standard corporate governance information and does not present new material risks.

Analyst Insight

Review the executive compensation details and any proposed shareholder resolutions in the DEF 14A to assess potential impacts on corporate governance and shareholder value.

Key Numbers

Key Players & Entities

FAQ

When did ARROWHEAD PHARMACEUTICALS, INC. file this DEF 14A?

ARROWHEAD PHARMACEUTICALS, INC. filed this Proxy Statement (DEF 14A) with the SEC on January 26, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ARROWHEAD PHARMACEUTICALS, INC. (ARWR).

Where can I read the original DEF 14A filing from ARROWHEAD PHARMACEUTICALS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ARROWHEAD PHARMACEUTICALS, INC..

What are the key takeaways from ARROWHEAD PHARMACEUTICALS, INC.'s DEF 14A?

ARROWHEAD PHARMACEUTICALS, INC. filed this DEF 14A on January 26, 2024. Key takeaways: Arrowhead Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 26, 2024.. The filing covers the period ending January 26, 2024.. The company's fiscal year ends on September 30..

Is ARROWHEAD PHARMACEUTICALS, INC. a risky investment based on this filing?

Based on this DEF 14A, ARROWHEAD PHARMACEUTICALS, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, which typically contains standard corporate governance information and does not present new material risks.

What should investors do after reading ARROWHEAD PHARMACEUTICALS, INC.'s DEF 14A?

Review the executive compensation details and any proposed shareholder resolutions in the DEF 14A to assess potential impacts on corporate governance and shareholder value. The overall sentiment from this filing is neutral.

How does ARROWHEAD PHARMACEUTICALS, INC. compare to its industry peers?

Arrowhead Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing innovative therapies.

Are there regulatory concerns for ARROWHEAD PHARMACEUTICALS, INC.?

As a publicly traded company, Arrowhead Pharmaceuticals is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.

Industry Context

Arrowhead Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing innovative therapies.

Regulatory Implications

As a publicly traded company, Arrowhead Pharmaceuticals is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.

What Investors Should Do

  1. Analyze the proposals presented in the DEF 14A for shareholder voting.
  2. Examine the executive compensation packages and any changes proposed.
  3. Review the board of directors' composition and any related governance matters.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document. No comparative data from a previous filing is directly presented in this extract.

Filing Stats: 4,592 words · 18 min read · ~15 pages · Grade level 13.9 · Accepted 2024-01-26 17:25:20

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 19 Compensation Discussion and Analysis 19 Our Company 19 Business Development 21 Platform 22 Pipeline 23

Executive Compensation Philosophy

Executive Compensation Philosophy 30

Executive Compensation Program Design

Executive Compensation Program Design 30 Governance of Executive Compensation Program 31 Individual Compensation Elements 33 Employment Arrangements 37 Post-Employment Compensation Arrangements 38 Other Compensation Policies and Practices 38 Tax and Accounting Considerations 39 Compensation Risk Assessment 40 Compensation Tables 41 Proposal Three — Ratification of Appointment of Independent Auditors 54 Audit Fees 55 Report of the Audit Committee 56 Voting Securities of Principal Stockholders and Management 57 Equity Compensation Plan Information 58 Review and Approval of Related-Party Transactions 60 Certain Relationships and Related Transactions, and Director Independence 61 Table of Contents 2024 PROXY STATEMENT General Information Concerning Solicitation and Voting ARROWHEAD PHARMACEUTICALS, INC. 177 E. Colorado Blvd., Suite 700 Pasadena, California 91105 (626) 304-3400 PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS To be held on Thursday, March 14, 2024 General Information Concerning Solicitation and Voting The enclosed Proxy is solicited on behalf of Arrowhead Pharmaceuticals, Inc. (the " Company " or " Arrowhead ") for use at the 2024 Annual Meeting of Stockholders (the " Annual Meeting ") to be held on Thursday, March 14, 2024 at 10:00 a.m., Pacific time, and at any adjournment(s) or postponement(s) thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Stockholders (the " Notice "). The Company anticipates that the Notice Regarding the Availability of Proxy Materials (the " Notice of Internet Availability ") in connection with these proxy solicitation materials will first be mailed on or about January 26, 2024 to all stockholders entitled to vote at the Annual Meeting and we will post our proxy materials on the website referenced in the Notice of Internet Availability. As more fully described in the Notice of Internet Availability, all stockholders may ch

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing